Promising prospects for 44Sc-/47Sc-based theragnostics: Application of 47Sc for radionuclide tumor therapy in mice

Journal of Nuclear Medicine

Volumn 55, Issue 10, 2014, Pages 1658-1664

  Müller, Cristina ^a   Bunka, Maruta ^b,c   Haller, Stephanie ^a   Köster, Ulli ^d   Groehn, Viola ^e   Bernhardt, Peter ^f,g   Van Der Meulen, Nicholas ^b   Türler, Andreas ^b,c   Schibli, Roger ^a,h  

^a ETH Zurich   (Switzerland)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d INSTITUT LAUE LANGEVIN   (France)

^e Merck and Cie   (Switzerland)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h ETH ZURICH   (Switzerland)

Author keywords

47Sc; Folate receptor; Folic acid; Radionuclide therapy; SPECT

Indexed keywords

AMMONIUM ACETATE; CALCIUM 46; CALCIUM 47; RADIOPHARMACEUTICAL AGENT; SCANDIUM 44; SODIUM CHLORIDE; TETRAXETAN FOLATE CONJUGATE SC 47; UNCLASSIFIED DRUG; CALCIUM; FOLATE RECEPTOR; SCANDIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KB CELL LINE; MOUSE; NEOPLASM; NONHUMAN; RADIOACTIVITY; RADIOCHEMISTRY; RADIOISOTOPE THERAPY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL TIME; TUMOR GROWTH; ANIMAL; CHEMISTRY; ION EXCHANGE CHROMATOGRAPHY; METABOLISM; NEOPLASMS; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RADIOTHERAPY; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; CALCIUM RADIOISOTOPES; CELL LINE, TUMOR; CHROMATOGRAPHY, ION EXCHANGE; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; MICE; MICE, NUDE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY; SCANDIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84907537302     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.141614     Document Type: Review

References (28)

1. Rösch F, Baum RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans. 2011;40: 6104-6111.
2. Lopci E, Chiti A, Castellani MR, et al. Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies. Eur J Nucl Med Mol Imaging. 2011;38(suppl 1):S28-S40.
3. Walrand S, Flux GD, Konijnenberg MW, et al. Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Yor 90Y imaging? Eur J Nucl Med Mol Imaging. 2011;38(suppl 1):S57-S68.
4. Anderson CJ, Dehdashti F, Cutler PD, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42: 213-221.
5. Anderson CJ, Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm. 2009;24:379-393.
6. O'Donnell RT, DeNardo GL, Kukis DL, et al. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med. 1999;40:2014-2020.
7. Lehenberger S, Barkhausen C, Cohrs S, et al. The low-energy beta- and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy. Nucl Med Biol. 2011;38:917-924.
8. Müller C, Zhernosekov K, Köster U, et al. A unique matched quadruplet of terbium radioisotopes for PETand SPECTand for α- and β-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. J Nucl Med. 2012;53:1951-1959.
9. Müller C, Reber J, Haller S, et al. Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate. Eur J Nucl Med Mol Imaging. 2014;41:476-485.
10. Roesch F. Scandium-44: benefits of a long-lived PET radionuclide available from the 44Ti/44Sc generator system. Curr Radiopharm. 2012;5:187-201.
11. Kolsky KL, Joshi V, Mausner LF, Srivastava SC. Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy. Appl Radiat Isot. 1998;49:1541-1549.
12. Polosak M, Piotrowska A, Krajewski S, Bilewicz A. Stability of 47Sc-complexes with acyclic polyamino-polycarboxylate ligands. J Radioanal Nucl Chem. 2013;295: 1867-1872.
13. Müller C, Bunka M, Reber J, et al. Promises of cyclotron-produced 44Sc as a diagnostic match for trivalent β-emitters: in vitro and in vivo study of a 44Sc-DOTA-folate conjugate. J Nucl Med. 2013;54:2168-2174.
14. Müller C, Struthers H, Winiger C, Zhernosekov K, Schibli R. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice. J Nucl Med. 2013;54:124-131.
15. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992;52: 3396-3401.
16. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338:284-293.
17. Majkowska-Pilip A, Bilewicz A. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals. J Inorg Biochem. 2011;105:313-320.
18. Dumelin CE, Trüssel S, Buller F, et al. A portable albumin binder from a DNAencoded chemical library. Angew Chem Int Ed Engl. 2008;47:3196-3201.
19. Reddy JA, Westrick E, Santhapuram HK, et al. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res. 2007;67: 6376-6382.
20. Sancéau J, Poupon MF, Delattre O, Sastre-Garau X, Wietzerbin J. Strong inhibition of Ewing tumor xenograft growth by combination of human interferonalpha or interferon-beta with ifosfamide. Oncogene. 2002;21:7700-7709.
21. Srivastava SC, Mausner LF, Mease RC. Criteria for the selection of radionuclides for tumor radioimmunotherapy. IAEA INIS website. http://www.iaea.org/inis/collection/NCLCollectionStore/-Public/23/010/23010630.pdf. Accessed July 3, 2014.
22. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
23. Yagi M, Kondo K. Preparation of carrier-free 47Sc by 48Ti (γ,p) reaction. Int J Appl Radiat Isot. 1977;28:463-468.
24. Kopecky P, Szelecsenyi F, Molnar T, Mikecz P, Tarkanyi F. Excitation-functions of (p, xn) reactions on natTi-monitoring of bombarding proton-beams. Appl Radiat Isot. 1993;44:687-692.
25. Mausner LF, Kolsky KL, Joshi V, Srivastava SC. Radionuclide development at BNL for nuclear medicine therapy. Appl Radiat Isot. 1998;49:285-294.
26. Habs D, Köster U. Production of medical radioisotopes with high specific activity in photonuclear reactions with gamma-beams of high intensity and large brilliance. Appl Phys B. 2011;103:501-519.
27. Bokhari TH, Mushtaq A, Khan IU. Separation of no-carrier-added radioactive scandium from neutron irradiated titanium. J Radioanal Nucl Chem. 2010;283:389-393.
28. Bartos B, Majkowska A, Kasperek A, Krajewski S, Bilewicz A. New separation method of no-carrier-added 47Sc from titanium targets. Radiochim Acta. 2012; 100:457-461.